LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 10 von insgesamt 180

Suchoptionen

  1. Artikel: Safeguards for medical aid in dying.

    Blanke, Charles D

    British journal of hospital medicine (London, England : 2005)

    2024  Band 85, Heft 2, Seite(n) 1

    Mesh-Begriff(e) Humans ; Suicide, Assisted/legislation & jurisprudence
    Sprache Englisch
    Erscheinungsdatum 2024-02-27
    Erscheinungsland England
    Dokumenttyp Letter
    ISSN 1750-8460
    ISSN 1750-8460
    DOI 10.12968/hmed.2024.0011a
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: To the Editor.

    Blanke, Charles D

    The American journal of bioethics : AJOB

    2023  Band 23, Heft 11, Seite(n) W1

    Sprache Englisch
    Erscheinungsdatum 2023-10-25
    Erscheinungsland United States
    Dokumenttyp Letter ; Comment
    ZDB-ID 2060433-6
    ISSN 1536-0075 ; 1526-5161
    ISSN (online) 1536-0075
    ISSN 1526-5161
    DOI 10.1080/15265161.2023.2263287
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Buch: Gastrointestinal oncology

    Blanke, Charles D.

    a practical guide

    2011  

    Verfasserangabe Charles D. Blanke ... (ed.)
    Schlagwörter Gastrointestinal Neoplasms / diagnosis ; Gastrointestinal Neoplasms / therapy ; Gastrointestinaler Krebs
    Schlagwörter Magen-Darm-Krebs ; Gastrointestinaltrakt
    Sprache Englisch
    Umfang VIII, 460 S. : Ill., graph. Darst., 235 mm x 155 mm
    Verlag Springer
    Erscheinungsort Berlin u.a.
    Erscheinungsland Deutschland
    Dokumenttyp Buch
    HBZ-ID HT016652496
    ISBN 978-3-642-13305-3 ; 9783642133060 ; 3-642-13305-3 ; 3642133061
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Zusatzmaterialien

    Kategorien

  4. Buch: Emerging strategies for the treatment of metastatic colorectal cancer

    Blanke, Charles D.

    (Community oncology ; 3,6, Suppl. 2)

    2006  

    Verfasserangabe Charles D. Blanke
    Serientitel Community oncology ; 3,6, Suppl. 2
    Überordnung
    Sprache Englisch
    Umfang 44 S. : graph. Darst.
    Verlag Elsevier
    Erscheinungsort Huntington, NY
    Erscheinungsland Vereinigte Staaten
    Dokumenttyp Buch
    HBZ-ID HT015282112
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Kategorien

  5. Buch: Gastroentestinal stromal tumours: perspectives on current diagnosis and therapy

    Blanke, Charles D.

    (EJC Supplements ; 4,3)

    2006  

    Verfasserangabe guest ed. Charles D. Blanke
    Serientitel EJC Supplements ; 4,3
    European journal of cancer
    Überordnung European journal of cancer
    Sprache Englisch
    Umfang 26 S. : graph. Darst.
    Verlag Elsevier
    Erscheinungsort Amsterdam u.a.
    Erscheinungsland Vereinigtes Königreich
    Dokumenttyp Buch
    HBZ-ID HT014739281
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: In response: Diabetes is a risk factor for the progression and prognosis of COVID-19.

    Blanke, Charles D

    Diabetes/metabolism research and reviews

    2020  Band 36, Heft 7, Seite(n) e3331

    Abstract: The article cited does not differentiate between Type I and Type II diabetes. More information is needed to properly assess risk. ...

    Abstract The article cited does not differentiate between Type I and Type II diabetes. More information is needed to properly assess risk.
    Schlagwörter covid19
    Sprache Englisch
    Erscheinungsdatum 2020-05-26
    Erscheinungsland England
    Dokumenttyp Letter
    ZDB-ID 1470192-3
    ISSN 1520-7560 ; 1520-7552
    ISSN (online) 1520-7560
    ISSN 1520-7552
    DOI 10.1002/dmrr.3331
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: The Gift of Dying With Control.

    Blanke, Charles D

    Practical radiation oncology

    2019  Band 9, Heft 6, Seite(n) 387–388

    Mesh-Begriff(e) Health Services Accessibility/standards ; Humans ; Suicide, Assisted/ethics
    Sprache Englisch
    Erscheinungsdatum 2019-09-13
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Personal Narrative
    ZDB-ID 2655748-4
    ISSN 1879-8519 ; 1879-8500
    ISSN (online) 1879-8519
    ISSN 1879-8500
    DOI 10.1016/j.prro.2019.09.002
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Novel Approach to Accelerate Lung Cancer Research: Lung-MAP and the Potential of Public-Private Partnerships.

    Herbst, Roy S / Blanke, Charles D / Sigal, Ellen V

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2023  Band 30, Heft 1, Seite(n) 29–32

    Abstract: The National Cancer Institute recently found that death rates for non-small cell lung cancer (NSCLC) have been reduced by over 6% overall in recent years. This reduction in mortality has been accompanied by an average increase in overall survival and ... ...

    Abstract The National Cancer Institute recently found that death rates for non-small cell lung cancer (NSCLC) have been reduced by over 6% overall in recent years. This reduction in mortality has been accompanied by an average increase in overall survival and largely credited to the therapeutic advancements for the effective treatment of NSCLC. Numerous molecular alterations have been identified in NSCLC that have enabled the development of new drugs capable of targeting these changes and efficiently kill cancerous cells. New treatments to modulate patients' immune systems have been shown to be effective in stimulating natural immune cells to have an improved anti-cancer effect. While these types of approaches to treat cancer are providing new options for patients, leadership from the Food and Drug Administration (FDA) recognized that the expansion of targeted therapy in NSCLC presented significant promise, but evaluation of the safety and efficacy of these new drugs would be slowed if new models for conducting clinical studies were not identified. Specifically, the FDA recommended that a comprehensive approach be implemented to identify the patients that are the best candidates for these, and other new treatments based upon the molecular characteristics of their tumors, and more efficiently conduct the clinical studies necessary to evaluate the safety and efficacy of new drugs. To address this growing challenge, leading lung cancer experts and stakeholders across academia, government, industry, and patient advocacy came together to design a clinical research approach that could serve as a sustainable infrastructure for new lung cancer treatments called the Lung Cancer Master Protocol.
    Mesh-Begriff(e) Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/pathology ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/pathology ; Public-Private Sector Partnerships ; Lung/pathology
    Sprache Englisch
    Erscheinungsdatum 2023-12-13
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-23-2690
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel: In response: Diabetes is a risk factor for the progression and prognosis of COVID-19

    Blanke, Charles D

    Diabetes Metab Res Rev

    Abstract: The article cited does not differentiate between Type I and Type II diabetes. More information is needed to properly assess risk. ...

    Abstract The article cited does not differentiate between Type I and Type II diabetes. More information is needed to properly assess risk.
    Schlagwörter covid19
    Verlag WHO
    Dokumenttyp Artikel
    Anmerkung WHO #Covidence: #378171
    Datenquelle COVID19

    Kategorien

  10. Artikel ; Online: In response

    Blanke, Charles D.

    Diabetes/Metabolism Research and Reviews ; ISSN 1520-7552 1520-7560

    Diabetes is a risk factor for the progression and prognosis of COVID ‐19

    2020  

    Schlagwörter Internal Medicine ; Endocrinology, Diabetes and Metabolism ; Endocrinology ; covid19
    Sprache Englisch
    Verlag Wiley
    Erscheinungsland us
    Dokumenttyp Artikel ; Online
    DOI 10.1002/dmrr.3331
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang